Andre Hoekema is Chief Business Officer at Galapagos, responsible for M&A, licensing and IP. He joined Galapagos early 2005 from Invitrogen, where he was Managing Director of Corp Dev Europe. He has 30 years of biotech experience from positions at Crucell, DSM/Gist-brocades, Syngenta MOGEN and Genentech. Dr. Hoekema has a PhD degree from Leiden University and is the inventor of over 20 series of patents. Over the years at Galapagos, he executed the pharma partnering strategy, including the deals with Servier, AbbVie, Novartis and Gilead.